LinkBlucon2

The LinkBluCon2 app can be used with the NightRider BluCon and Abbott's FreeStyle Libre 2 sensor to get near real-time glucose trends. If you are using any other Libre sensor use LinkBluCon app not LinkBluCon2 app

Type 1 and Type 2 diabetic patients can use this app to connect their iPhone to a BluCon device to read the Freestyle Libre 2 sensor every 5 minutes. Readings are available to the user through a user-friendly and intuitive GUI. This relieves the user from having to scan their sensor every 5 minutes. Internet connectivity is required for the app to work.
LinkBluCon2 connects to BluCon over a Bluetooth connection to display glucose trends. It also provides a history to view past readings. No sign-up is required.

Learn more about the LinkBluCon2 app and BluCon at https://www.AmbrosiaSys.com.

Please note that a fingerprick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycemia or impending hypoglycemia is reported by the LinkBluCon2 app or when symptoms do not match the LinkBluCon2 app readings.

By downloading this app or using or otherwise accessing this app you are agreeing to the End User Licence Agreement (https://www.ambrosiasys.com/eula) and the Terms of Use (https://www.ambrosiasys.com/terms).

You are now able to get glucose from all Libre sensors, using our latest app v1.0.2 or higher and latest Nightrider with firmware version 8.1 or higher

COMPATIBLE WITH ALL WEAROS
Blucon wear os app are compatible with all of the latest WearOS watches, including Asus ZenWatch, Casio Smart Watch, Fossil smartwatches, Guess Wear, Huawei Watch, Hublot Big Bang e, LG Watch, Louis Vuitton, Mobvoi TicWatch, Motorola Moto 360, Movado Connect, Movado Boss Touch, Montblanc Summit, New Balance Run, OPPO Watch, Polar M600, Samsung Galaxy Watch4, Sony SmartWatch 3, Suunto 7, TAG Heuer Connected, Verizon Wireless, ZTE and more

Note: Fingerpricks are required for all treatment decisions.